Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Daiichi Sankyo - Expanding the horizon for the treatment of solid tumors with antibody drug conjugates (ADCs)

Live Q&A + summary and close

Date

20 Nov 2020

Session

Daiichi Sankyo - Expanding the horizon for the treatment of solid tumors with antibody drug conjugates (ADCs)

Topics

Targeted Therapy

Tumour Site

Presenters

Hyun Cheol Chung

Authors

T.S.K. Mok1, R. Dent2, K. Park3, H.C. Chung4

Author affiliations

  • 1 Clinical Oncology Department, Prince of Wales Hospital, Shatin/HK
  • 2 NCCS - National Cancer Centre Singapore, 169610 - Singapore/SG
  • 3 Ivision Of Hematology/oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 06351 - Seoul/KR
  • 4 Medical Oncology, Severance Hospital, Seoul/KR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.